Evogene Analyst Ratings
Evogene Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/21/2023 | 417.24% | Roth MKM | $1 → $6 | Maintains | Buy |
| 05/02/2023 | 72.41% | Lake Street | → $2 | Initiates Coverage On | → Buy |
| 09/12/2022 | 589.66% | Aegis Capital | $10 → $8 | Maintains | Buy |
| 10/08/2021 | 503.45% | Roth Capital | → $7 | Initiates Coverage On | → Buy |
| 07/29/2021 | 762.07% | Aegis Capital | → $10 | Initiates Coverage On | → Buy |
| 12/01/2020 | 675.86% | Cantor Fitzgerald | → $9 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/21/2023 | 417.24% | Roth MKM | $1 → 6 美元 | 維護 | 購買 |
| 05/02/2023 | 72.41% | 湖街 | → 2 美元 | 啓動覆蓋開啓 | → 購買 |
| 2022 年 12 月 9 日 | 589.66% | 宙斯盾資本 | 10 美元 → 8 美元 | 維護 | 購買 |
| 2021 年 8 月 10 日 | 503.45% | 羅斯資本 | → 7 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 7 月 29 日 | 762.07% | 宙斯盾資本 | → 10 美元 | 啓動覆蓋開啓 | → 購買 |
| 12/01/2020 | 675.86% | 坎託·菲茨傑拉德 | → 9 美元 | 啓動覆蓋開啓 | → 超重 |
What is the target price for Evogene (EVGN)?
Evogene（EVGN）的目標價格是多少？
The latest price target for Evogene (NASDAQ: EVGN) was reported by Roth MKM on July 21, 2023. The analyst firm set a price target for $6.00 expecting EVGN to rise to within 12 months (a possible 417.24% upside). 3 analyst firms have reported ratings in the last year.
Roth MKM於2023年7月21日公佈了Evogene（納斯達克股票代碼：EVGN）的最新目標股價。這家分析公司將目標股價定爲6.00美元，預計EVGN將在12個月內升至6美元（可能上漲417.24％）。去年有3家分析公司公佈了評級。
What is the most recent analyst rating for Evogene (EVGN)?
分析師對Evogene（EVGN）的最新評級是多少？
The latest analyst rating for Evogene (NASDAQ: EVGN) was provided by Roth MKM, and Evogene maintained their buy rating.
Evogene（納斯達克股票代碼：EVGN）的最新分析師評級由Roth MKM提供，Evogene維持買入評級。
When is the next analyst rating going to be posted or updated for Evogene (EVGN)?
Evogene（EVGN）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evogene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evogene was filed on July 21, 2023 so you should expect the next rating to be made available sometime around July 21, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Evogene的高管和客戶交談以及聽取業績電話會議）後得出股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Evogene的最後一次評級是在2023年7月21日提交的，因此您應該預計下一個評級將在2024年7月21日左右公佈。
Is the Analyst Rating Evogene (EVGN) correct?
分析師對Evogene (EVGN) 的評級是否正確？
While ratings are subjective and will change, the latest Evogene (EVGN) rating was a maintained with a price target of $1.00 to $6.00. The current price Evogene (EVGN) is trading at is $1.16, which is within the analyst's predicted range.
雖然評級是主觀的，會發生變化，但最新的Evogene（EVGN）評級維持不變，目標股價爲1.00美元至6.00美元。Evogene（EVGN）目前的交易價格爲1.16美元，在分析師的預測區間內。